source
- GSK receives FDA accelerated approval for neladalkib (Nelkarmi) in ALK-positive lung cancer, second win from Nuvalent dealGSK announced that the FDA has granted accelerated approval to its tyrosine kinase inhibitor neladalkib, to be sold under the brand name Nelkarmi, for patients with ALK‑positive non‑small cell lung…
- FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live LongerFDA approved Lembaz (adrabetadex) injection, the first treatment shown to help people with a severe form of Niemann-Pick disease type C (NPC) live longer.